Slide 17 from the AGM presentation below, highlighted the progress validation of FPP peptide vaccine for subcutaneous melanoma model engineered to express glycoprotein from the Herpes Simplex Virus.
http://www.finnewsnetwork.com.au/Presentations/Phylogica/PYC_2017_AGM/index.html
Now isn't Talimogene (T-Vec) an interesting advancement for melanoma therapy, particularly when used in combination with some of the other well known immunotherapy treatments already on the market.
https://www.doctorportal.com.au/mjainsight/2016/46/talimogene-first-ever-melanoma-vaccine/
https://www.healio.com/hematology-o...egimen-improves-survival-in-advanced-melanoma
https://en.wikipedia.org/wiki/Talimogene_laherparepvec
Tony
Ann: Phylogica Strategic Update - Pivot to Platform, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $376.6K | 296.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15688 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.27 | 16966 | 3 |
View Market Depth
| Last trade - 15.20pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |